SRTSW - (Sensus Healthcare Inc.)

SRTSWのニュース

   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.

calendar